What Is Cagrilintide?
Cagrilintide is a long-acting synthetic analog of amylin — a 37-amino-acid peptide hormone that is co-secreted with insulin by pancreatic beta cells in response to nutrient ingestion. Native amylin has a plasma half-life of only a few minutes, limiting its utility in extended research protocols. Cagrilintide achieves approximately one-week plasma half-life through a set of structural modifications that confer both protease resistance and albumin binding.Cagrilintide is studied both as a standalone tool for amylin receptor biology research and as a component of the CagriSema combination (cagrilintide + semaglutide), which has been investigated in published Phase 3 clinical trials for metabolic endpoints.
Phase 1 Peptides supplies cagrilintide as a research compound for laboratory use only.
Amylin Biology: The Native Peptide
Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide hormone produced by pancreatic beta cells and co-packaged with insulin in secretory granules. It is co-released with insulin in response to meals. In the research literature, native amylin has been studied for its role in:- Central neuroendocrine signaling: Amylin receptors are expressed in the brainstem (area postrema) and hypothalamic nuclei (including the arcuate nucleus) — regions involved in energy homeostasis regulation. Area postrema amylin receptor activation is particularly well-characterized and does not require BBB penetration because the area postrema is a circumventricular organ outside the BBB.
- Gastric motility: Amylin reduces gastric emptying rate in research models — a mechanism that is pharmacologically complementary to (but distinct from) GLP-1R-mediated gastric motility effects
- Glucagon suppression: Amylin signaling reduces glucagon secretion via poorly characterized central and paracrine pathways
- Beta cell biology: Native amylin at high concentrations forms amyloid fibrils that are associated with beta cell toxicity in type 2 diabetes research models — a research application distinct from cagrilintide's modified structure
Amylin Receptor Pharmacology
Amylin receptors are heterodimeric complexes formed by the calcitonin receptor (CTR) combined with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These complexes are designated:
- AMY1R (CTR + RAMP1)
- AMY2R (CTR + RAMP2)
- AMY3R (CTR + RAMP3)
The RAMP subunit determines the binding pharmacology — amylin preferentially activates AMY1R and AMY3R, while CTR alone (without RAMP) is preferentially activated by calcitonin. This makes amylin receptor pharmacology structurally distinct from typical class B GPCR agonism: receptor identity depends on which RAMP is co-expressed in a given cell type.
Cagrilintide binds the same CTR/RAMP complexes as native amylin, with the structural modifications providing extended plasma durability rather than altered receptor selectivity.
Structural Modifications: Achieving Weekly Dosing
Native amylin's pharmacological limitations — short half-life, tendency to aggregate — are addressed in cagrilintide through three key modifications:
1. Alanine substitution at position 25: The substitution at Ala²⁵ reduces amyloid aggregation propensity, a property of native amylin that has been characterized in published biophysical research. This modification improves solution stability and reduces the aggregation risk that has complicated earlier amylin analog research.
2. C-terminal amidation: Standard for amylin, preserved in cagrilintide. C-terminal amidation is a common peptide modification that protects against carboxypeptidase degradation and is often required for receptor recognition in amylin biology.
3. C20 fatty acid chain via linker: A 20-carbon fatty acid is conjugated to the peptide via a linker, enabling reversible albumin binding in plasma. This is the same albumin-binding strategy used in semaglutide and other long-acting peptide analogs — it extends plasma half-life to approximately one week by creating a large albumin-bound reservoir that buffers against renal clearance and proteolysis.
CagriSema: Amylin/GLP-1 Combination Research
CagriSema — the combination of cagrilintide + semaglutide — represents the primary published clinical research context for cagrilintide. The rationale for combining an amylin-axis compound with a GLP-1R agonist is mechanistic complementarity:- GLP-1R agonism (semaglutide) engages the incretin axis — insulin secretion, gastric emptying, and central GLP-1R circuits in the arcuate nucleus and hindbrain
- Amylin receptor agonism (cagrilintide) engages the amylin axis — area postrema/NTS circuitry, complementary gastric motility effects, and glucagon suppression via a different central circuit
Published research has proposed that these two axes, while partly overlapping at the level of downstream endpoints, act on partially non-overlapping central and peripheral receptor populations — providing a rationale for combination research beyond simple additive effects.
Published Phase 3 CagriSema clinical trial data (the REDEFINE trials) is available in the peer-reviewed literature and provides reference endpoints for researchers examining GLP-1/amylin axis biology in clinical-scale datasets.
Research Utility: Amylin Axis Isolation
As a standalone compound, cagrilintide provides a research tool for studying amylin receptor biology with:
- Once-weekly dosing window — suitable for sustained-exposure animal model designs without daily injection protocols
- Structural stability — reduced aggregation propensity vs native amylin in research preparations
- Published receptor pharmacology — CTR/RAMP characterization is available for contextualizing findings against published reference data
For GLP-1R biology as a comparison or combination axis, see the Tirzepatide vs. Semaglutide comparison and Retatrutide research primer.
Laboratory Handling Notes
Cagrilintide is supplied as a lyophilized powder. Its fatty acid modification contributes lipophilicity — dissolve with gentle mixing to ensure complete reconstitution. Reconstitute in bacteriostatic water or the buffer specified in your research protocol. Store lyophilized at −20 °C; reconstituted solutions at 2–8 °C. See the reconstitution guide for standard workflow.
Product Availability
Phase 1 Peptides stocks Cagrilintide at 99%+ purity with third-party laboratory documentation.
Q: How is cagrilintide different from pramlintide?Pramlintide (Symlin) is an earlier synthetic amylin analog approved for clinical use in type 1 and type 2 diabetes research populations. It uses a different modification strategy (three proline substitutions to prevent aggregation), lacks a fatty acid chain for albumin binding, and has a much shorter half-life (approximately 48 minutes) — requiring multiple daily administrations in published clinical protocols. Cagrilintide's fatty acid modification allows once-weekly dosing, making it more practical for extended research designs. Pramlintide is the published clinical pharmacology reference for amylin-axis agonism; cagrilintide extends this into the long-acting once-weekly framework.
Q: What is the area postrema and why is it relevant to amylin research?The area postrema is a circumventricular organ in the dorsal brainstem — a region that lies outside the blood-brain barrier and therefore has direct exposure to circulating plasma peptides. It is densely populated with AMY1R (CTR/RAMP1) expressing neurons that project to the nucleus of the solitary tract (NTS). This positioning makes the area postrema a primary site for amylin's central signaling effects: peripherally administered amylin (and cagrilintide) accesses area postrema AMY1R without requiring BBB penetration. In research models, area postrema lesioning studies have been used to confirm that amylin's central effects are mediated through this circuitry.
Q: What is the REDEFINE trial and why is it relevant to laboratory research?REDEFINE is the Phase 3 clinical trial program for CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly). Published REDEFINE results provide a large-scale human clinical dataset characterizing GLP-1/amylin axis biology across metabolic parameters over 68 weeks. For laboratory researchers, these datasets offer a human reference framework for validating in vitro or animal model findings in the context of GLP-1R + amylin receptor co-activation.
For a comparative overview of GLP-1R agonist research peptides including cagrilintide's placement in the amylin/GLP-1 research landscape, see the GLP-1 Receptor Agonist Research Landscape.
See Also
- Mazdutide Research Primer
- Retatrutide Research Primer
- Peptide Half-Life Reference
- Lab Testing & Verified Purity
- Peptide Storage & Stability
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.